We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
O8‐3: The effectiveness of the combined use of remdesivir and regdanvimab (CT‐P59) in patients with severe COVID‐19: A single center retrospective study.
- Abstract
1 Ulsan University Hospital, University of Ulsan College of Medicine, Korea B Background b : Although the use of remdesivir and systemic corticosteroids have reduced deaths from COVID-19, COVID-19 still has a high mortality rate. Further, in the regdanvimab/remdesivir group, the lowest SpO SB 2 sb /FiO SB 2 sb ratio during treatment was significantly higher (mean ± SD: 237.05 ± 89.68 vs. 295.63 ± 72.74, P = 0.003), and the Kaplan-Meier Estimate of oxygen supplement days in surviving patients (at day 28) were significantly shorter (mean ± SD: 8.24 ± 7.43 vs. 5.28 ± 3.66, P (log-rank test) = 0.024). B Methods b : From March to early May 2021, 124 severe COVID-19 patients were admitted to Ulsan University Hospital (Ulsan, Korea), and received oxygen therapy and remdesivir.
- Subjects
COVID-19; REMDESIVIR; RETROSPECTIVE studies; TREATMENT effectiveness
- Publication
Respirology, 2021, Vol 26, p23
- ISSN
1323-7799
- Publication type
Article
- DOI
10.1111/resp.14149_46